AR033288A1 - Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes - Google Patents

Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes

Info

Publication number
AR033288A1
AR033288A1 ARP020101574A ARP020101574A AR033288A1 AR 033288 A1 AR033288 A1 AR 033288A1 AR P020101574 A ARP020101574 A AR P020101574A AR P020101574 A ARP020101574 A AR P020101574A AR 033288 A1 AR033288 A1 AR 033288A1
Authority
AR
Argentina
Prior art keywords
manufacturing
pharmaceutical composition
uniform
pharmaco
distribution
Prior art date
Application number
ARP020101574A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR033288A1 publication Critical patent/AR033288A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un método para fabricar una composicion farmacéutica que tiene una distribucion y potencia del fármaco uniformes, el cual utiliza dioxido de silicio para reducir la pérdida de ingrediente activo durante el proceso de fabricacion. El método es particularmente util para la fabricacion de composiciones para comprimidos de baja dosificacion.
ARP020101574A 2001-05-01 2002-04-29 Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes AR033288A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28784101P 2001-05-01 2001-05-01

Publications (1)

Publication Number Publication Date
AR033288A1 true AR033288A1 (es) 2003-12-10

Family

ID=23104578

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101574A AR033288A1 (es) 2001-05-01 2002-04-29 Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes

Country Status (44)

Country Link
US (2) US7037530B2 (es)
EP (1) EP1383482B1 (es)
JP (1) JP2004531537A (es)
KR (1) KR100568380B1 (es)
CN (1) CN1240375C (es)
AP (1) AP2003002900A0 (es)
AR (1) AR033288A1 (es)
AT (1) ATE367152T1 (es)
AU (1) AU2002236166B2 (es)
BG (1) BG108297A (es)
BR (1) BR0209283A (es)
CA (1) CA2445519C (es)
CZ (1) CZ20032959A3 (es)
DE (1) DE60221238T2 (es)
DK (1) DK1383482T3 (es)
DO (1) DOP2002000389A (es)
EA (1) EA005949B1 (es)
EC (1) ECSP034826A (es)
EE (1) EE200300537A (es)
ES (1) ES2286226T3 (es)
GE (1) GEP20053654B (es)
GT (1) GT200200078A (es)
HK (1) HK1065705A1 (es)
HR (1) HRP20030858A2 (es)
HU (1) HUP0401391A3 (es)
IL (1) IL158390A0 (es)
IS (1) IS6985A (es)
MA (1) MA27017A1 (es)
MX (1) MXPA03009391A (es)
NO (1) NO20034709L (es)
NZ (1) NZ528886A (es)
OA (1) OA12596A (es)
PA (1) PA8544401A1 (es)
PE (1) PE20021137A1 (es)
PL (1) PL366453A1 (es)
PT (1) PT1383482E (es)
SK (1) SK286536B6 (es)
TN (1) TNSN03106A1 (es)
TW (1) TWI264311B (es)
UA (1) UA75135C2 (es)
UY (1) UY27277A1 (es)
WO (1) WO2002087546A2 (es)
YU (1) YU81503A (es)
ZA (1) ZA200307819B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009259A (es) 2002-03-28 2005-01-25 Pfizer Prod Inc Lasofoxifeno racemico purificado y d-tartrato de lasofoxifeno purificado y un metodo para la purificacion efectiva del lasofoxifeno racemico.
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en) 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
EP2023745A1 (en) * 2006-05-17 2009-02-18 WM. Wrigley Jr., Company Method of preparing a food product
FI20070521L (fi) 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
FI20080351A0 (fi) * 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
US8951562B2 (en) 2006-11-10 2015-02-10 Atacama Labs Oy Method and apparatus or dry granulation
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
US20080181972A1 (en) * 2007-01-29 2008-07-31 Valentina Amico Compositions and Methods for Maintaining, Strengthening, Improving, or Promoting Eye Health
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
EP2291233B1 (en) * 2008-05-09 2019-09-04 Atacama Labs Oy Method for dry granulation
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
EA029996B1 (ru) 2008-06-06 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Капсулярная лекарственная форма, содержащая суспензионную композицию производного индолинона
ES2520990T3 (es) * 2009-01-29 2014-11-12 Ucb Pharma, S.A. Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina
CN104083328B (zh) * 2009-01-29 2017-04-12 Ucb生物制药私人有限公司 包含2‑氧代‑1‑吡咯烷衍生物的药物组合物
US20140350945A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America System and Method for Validation of Pharmaceutical Composition Formulations
CN103830196A (zh) * 2014-03-14 2014-06-04 王志刚 一种酒石酸拉索昔芬分散片及其制备方法
CN106176649B (zh) * 2016-08-31 2020-04-17 北京斯利安药业有限公司 叶酸vb12片及其制备方法
MX2019009777A (es) * 2017-02-17 2019-10-14 Massachusetts Inst Technology Sistemas y metodos para la fabricacion de tabletas, que incluyen tabletas farmaceuticas.
CZ309820B6 (cs) * 2021-04-23 2023-11-08 Pro.Med.Cs Praha A.S. Způsob přípravy pevné lékové formy obsahující kompozici s nízkým obsahem účinné látky

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725555A (en) * 1967-08-01 1973-04-03 Ciba Geigy Corp Bactericidal compositions and method of killing bacteria using bis-(phenoxyphenyl) carbonates
US3725556A (en) * 1970-11-12 1973-04-03 D Hanssen Method of manufacturing rapidly disintegrating pharmaceutical tablets
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
GB1570993A (en) * 1976-05-21 1980-07-09 Fisons Ltd Pharmaceutical tablet formulation
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5107331A (en) * 1989-03-07 1992-04-21 The Color Group Method and apparatus for producing half-tone separations at the same screen angle
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5976570A (en) * 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
JPH10204082A (ja) * 1996-10-25 1998-08-04 Eli Lilly & Co 選択的エストロゲンレセプターモジュレーターとしての活性を有する置換されたベンゾ［ｂ］チオフェン化合物
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
EP0889056B1 (en) * 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
US6300367B1 (en) * 1999-04-20 2001-10-09 Protein Technologies International, Inc. Composition for and method of preventing or treating breast cancer
US6555551B1 (en) * 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos

Also Published As

Publication number Publication date
MA27017A1 (fr) 2004-12-20
ES2286226T3 (es) 2007-12-01
ZA200307819B (en) 2004-10-07
HK1065705A1 (en) 2005-03-04
ATE367152T1 (de) 2007-08-15
CA2445519C (en) 2009-01-20
EA200301040A1 (ru) 2004-04-29
MXPA03009391A (es) 2004-01-29
IS6985A (is) 2003-10-09
CN1240375C (zh) 2006-02-08
DE60221238T2 (de) 2007-10-31
HUP0401391A3 (en) 2009-06-29
BR0209283A (pt) 2004-07-13
GEP20053654B (en) 2005-11-10
CA2445519A1 (en) 2002-11-07
US7037530B2 (en) 2006-05-02
HRP20030858A2 (en) 2005-08-31
TNSN03106A1 (fr) 2005-12-23
US20060093667A1 (en) 2006-05-04
AP2003002900A0 (en) 2003-12-31
CN1531423A (zh) 2004-09-22
NO20034709D0 (no) 2003-10-21
OA12596A (en) 2006-06-08
PE20021137A1 (es) 2002-12-14
DOP2002000389A (es) 2002-11-30
IL158390A0 (en) 2004-05-12
WO2002087546A3 (en) 2003-02-13
BG108297A (bg) 2005-07-29
EP1383482A2 (en) 2004-01-28
NZ528886A (en) 2005-04-29
SK13552003A3 (sk) 2004-09-08
UA75135C2 (en) 2006-03-15
CZ20032959A3 (cs) 2004-01-14
GT200200078A (es) 2003-01-31
PL366453A1 (en) 2005-02-07
KR20040015226A (ko) 2004-02-18
SK286536B6 (sk) 2008-12-05
PT1383482E (pt) 2007-09-20
US7176221B2 (en) 2007-02-13
JP2004531537A (ja) 2004-10-14
AU2002236166B2 (en) 2006-12-07
US20030004182A1 (en) 2003-01-02
HUP0401391A2 (hu) 2004-12-28
EE200300537A (et) 2004-04-15
WO2002087546A2 (en) 2002-11-07
TWI264311B (en) 2006-10-21
YU81503A (sh) 2006-08-17
DK1383482T3 (da) 2007-10-29
NO20034709L (no) 2003-10-31
EP1383482B1 (en) 2007-07-18
EA005949B1 (ru) 2005-08-25
PA8544401A1 (es) 2003-07-28
ECSP034826A (es) 2004-02-26
KR100568380B1 (ko) 2006-04-05
UY27277A1 (es) 2002-11-29
DE60221238D1 (de) 2007-08-30

Similar Documents

Publication Publication Date Title
AR033288A1 (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
PE20030823A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
ES2191977T3 (es) Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.
SE0100568D0 (sv) Compounds
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
ATE478841T1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
GT199900203A (es) Composiciones de celecoxib.
DK1746980T3 (da) Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
WO2005097076A3 (en) Low dose pharmaceutical products
PE20150773A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilefrina
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
SE0100566D0 (sv) Compounds
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
AR026010A1 (es) Unidad de dosificacion oral que se desintegra oralmente conteniendo como ingrediente activo el antidepresivo mirtazapina
ECSP003685A (es) Formulaciones orales de liberacion controlada
CR7117A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
SE0000303D0 (sv) Novel compounds
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
RU2008115908A (ru) Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения
DOP2003000655A (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
HN2003000048A (es) Comprimido de nelfinavir de dosis incrementada y metodo para fabricarlo
AR032585A1 (es) Procedimiento para preparar composiciones farmaceuticas en comprimidos de desintegracion rapida sustancialmente exentos de cristales del principio farmacologicamente activo provenientes de la modificacion de la estructura cristalina de dicho agente durante las operaciones de fabricacion de los mismo
NO20034873D0 (no) Bredspektret 2-(amino)-benzoxazolsulfonamid HIV proteasehemmere

Legal Events

Date Code Title Description
FB Suspension of granting procedure